340B Prime Vendor Apexus Asks Court to Dismiss AIDS Healthcare Foundation’s Breach of Contract Suit

USDC Central District of California building with Great Seal of the United States
The 340B prime vendor Apexus asked the federal district court in Los Angeles to dismiss AIDS Healthcare Foundation's claims that Apexus failed and refused to negotiate sub-ceiling discounts on HIV/AIDS drugs.

Apexus, the federally contracted 340B prime vendor, asked a federal district judge in Los Angeles on Friday to dismiss AIDS Healthcare Foundation’s lawsuit alleging that Apexus has failed and refused to negotiate sub-ceiling 340B discounts on HIV/AIDS prescription drugs pursuant

Read More »

News Alert

Some Provider Groups Slam NACHC and PhRMA’s 340B Plan, Others Say They’re Studying it

NACHC P&I 2023 speaker at podium
Lt. Cmdr. Emeka Egwim (left), Director of HRSA's Office of Pharmacy Affairs, spoke this morning on 340B Day at NACHC's annual Policy & Issues Forum in Washington, D.C.

A large HIV/AIDS health care group, a Democratic 340B provider ally in Congress, and three national hospital groups lambasted community health centers and drug makers’ historic announcement yesterday that they are working together to remake the 340B program. Other 340B

Read More »

U.S. House Subcommittee Expected to Raise 340B During March 28 Hearing

House E&C wordmark
Provider groups criticized draft legislation to address drug shortages from the House Energy and Commerce Committee.

The Republican-led U.S. House Energy & Commerce health subcommittee late yesterday announced a March 28 hearing on “how transparency and competition can lower health care costs for Americans.”

Although the hearing announcement is silent about the 340B program it

Read More »

Breaking News

Major Drug Industry and Health Center Groups Unite to Reform 340B for Patients and “True” Safety-Net Providers

ASAP 340B wordmark
PhRMA, NACHC, and and the National Hispanic Medical Association created a new group, ASAP 340B, and issued a 10-point plan to ensure that the 340B program “benefits patients and true safety-net providers, including rural hospitals.”

Pharmaceutical Research and Manufacturers of America, the National Association of Community Health Centers, and the National Hispanic Medical Association this morning jointly issued a 10-point plan and created a nonprofit group to ensure that the 340B program “benefits patients and

Read More »

N.Y. State Judge Dismisses 340B-Related Antitrust Suit Against CVS

CVS Health signage
A New York State judge dismissed the state attorney general's 340B-related antitrust lawsuit against CVS Health.

A New York State judge has dismissed the state’s antitrust lawsuit alleging that CVS Health illegally makes 340B covered entities use its 340B third party administrator Wellpartner in order to contract with CVS retail and specialty pharmacies to dispense 340B-purchased

Read More »

Amneal Offering 340B Refunds on Long List of Drugs for Sales Between Q3 2019 and Q3 2022

Amneal wordmark on building
Amneal Pharmaceuticals is offering refunds for 340B overcharges on an 18-page-long list of products for purchases between Q3 2019 and Q3 2022.

Generic and specialty drug manufacturer Amneal Pharmaceuticals is offering refunds for 340B overcharges on an 18-page-long list of products for purchases between Q3 2019 and Q3 2022.

The U.S. Health Resources and Services Administration posted New Jersey-based Amneal’s notice to

Read More »

NACHC Hill Day Document Calls for 340B Reform and Offers Guiding Principles, Key Hill Staffer Joins Organization

NACHC image of core principles for 340B reform
“Health centers and their patients cannot afford more [contract pharmacy] restrictions or PBM discriminatory contracting," NACHC says in document urging Congress "to amend the 340B statute to protect access for the true safety-net providers.”

The National Association of Community Health Centers says in a new advocacy document “it’s time to reform the 340B program to recognize the complexities of today’s healthcare system and ensure that true safety-net providers continue to have access to critical

Read More »

Bottom Line, not Altruism, Could be the Main Driver of Lilly’s Insulin Price Cut, Drug Pricing Expert Says

Humalog vial
Lilly's decision to cut the price of its fast-acting insulin Humalog might have been driven by a desire to avoid exposure to Medicaid rebates, drug pricing expert Sean Dickson says.

Drug manufacturer Lilly’s announcement last week that it is slashing the price of Humalog, its most commonly prescribed insulin, may have been less about altruism and more about avoiding exposure to bigger Medicaid rebates, a prominent drug pricing expert says.

Read More »

News Alert

340B Raised Often During Senate Hearing on Community Health Centers

Sen. Bill Cassidy pictured at a hearing
Sen. Bill Cassidy (R-La.) asked a witness during a hearing if she was open to 340B reforms to ensure that 340B savings “are not going to build a chandelier in a hospital et cetera.”

The 340B program—and whether it needs change, protection, or both—came up often today during a U.S. Senate hearing on federal funding of community health centers.

The bulk of health centers’ federal grant funding—about $5.8 billion annually from the U.S. Health

Read More »

Health Centers and PhRMA Co-Developing 340B Policies, Hospital Group Says

NACHC and PhRMA wordmarks
NACHC and PhRMA are jointly developing 340B policy proposals for Congress to consider, hospital group 340B Health says.

Associations representing community health centers and brand drug manufacturers are jointly developing 340B policy proposals for Congress to consider, hospital group 340B Health told its members yesterday.

The National Association of Community Health Centers said yesterday that it had no

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report